Share-based Payment Arrangement, Expense of Lyell Immunopharma, Inc. from 31 Dec 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Lyell Immunopharma, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2019 to 30 Sep 2025.
  • Lyell Immunopharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $5,232,000, a 31% decline year-over-year.
  • Lyell Immunopharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $24,343,000, a 27% decline year-over-year.
  • Lyell Immunopharma, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $33,144,000, a 30% decline from 2023.
  • Lyell Immunopharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $47,084,000, a 43% decline from 2022.
  • Lyell Immunopharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $81,924,000, a 32% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Lyell Immunopharma, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $24,343,000 $5,232,000 -$2,390,000 -31% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $26,733,000 $5,004,000 -$3,280,000 -40% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $30,013,000 $6,024,000 -$3,131,000 -34% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $33,144,000 $8,083,000 -$380,000 -4.5% 01 Oct 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
Q3 2024 $33,524,000 $7,622,000 -$2,894,000 -28% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $36,418,000 $8,284,000 -$5,939,000 -42% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $42,357,000 $9,155,000 -$4,727,000 -34% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $47,084,000 $8,463,000 -$9,900,000 -54% 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
Q3 2023 $56,984,000 $10,516,000 -$8,607,000 -45% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $65,591,000 $14,223,000 -$8,187,000 -37% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $73,778,000 $13,882,000 -$8,146,000 -37% 01 Jan 2023 31 Mar 2023 10-Q 06 May 2024 2024 Q1
Q4 2022 $81,924,000 $18,363,000 -$2,815,000 -13% 01 Oct 2022 31 Dec 2022 10-K 11 Mar 2025 2024 FY
Q3 2022 $84,739,000 $19,123,000 +$6,081,000 +47% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $78,658,000 $22,410,000 +$7,161,000 +47% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $71,497,000 $22,028,000 +$9,296,000 +73% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $62,201,000 $21,178,000 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
Q3 2021 $13,042,000 +$3,294,000 +34% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $15,249,000 +$7,981,000 +110% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $12,732,000 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q3 2020 $9,748,000 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $7,268,000 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2

Lyell Immunopharma, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $33,144,000 -$13,940,000 -30% 01 Jan 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
2023 $47,084,000 -$34,840,000 -43% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
2022 $81,924,000 +$19,723,000 +32% 01 Jan 2022 31 Dec 2022 10-K 11 Mar 2025 2024 FY
2021 $62,201,000 +$28,940,000 +87% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
2020 $33,261,000 +$17,529,000 +111% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $15,732,000 01 Jan 2019 31 Dec 2019 10-K 29 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.